MiCheck® Prostate
MiCheck® Prostate LDT is intended for use as an aid to clinicians in the decision to proceed to prostate biopsy in patients with an abnormal PSA.
- MiCheck® Prostate provides an estimate of the risk of aggressive prostate cancer.
- MiCheck® Prostate has demonstrated the ability to differentiate aggressive from non-aggressive cancer and no cancer.
- MiCheck® Prostate demonstrates a compelling advantage in specificity over existing products, outperforming the benchmark PSA test as well as other tests such as % free PSA and the Prostate Health Index (PHI) in a head-to-head comparison.
- The lack of specificity of other tests has led to criticism due to the resulting unnecessary biopsies. MiCheck® Prostate helps fill this substantial unmet clinical need by allowing a reduction in number of biopsies while minimising the risk of missing out aggressive prostate cancer cases.
MiCheck® Prostate also offers:
✔ Ease of use – blood collection made at the same time as the blood draw for a PSA test.
✔ No interruption to the clinician’s current workflow.
✔ Clear clinical utility – single page well-defined report to help the clinician determine whether the patient needs a biopsy or future follow-up in the coming months.
✔ Timely delivery of results – ready for the patient’s next visit to the clinician.
✔ Dominant health economics in comparison to standard of care.
✔ Early availability as a LDT through a CLIA certified high complexity laboratory.
✔ Ease of use – blood collection made at the same time as the blood draw for a PSA test.
✔ No interruption to the clinician’s current workflow.
✔ Clear clinical utility – single page well-defined report to help the clinician determine whether the patient needs a biopsy or future follow-up in the coming months.
✔ Timely delivery of results – ready for the patient’s next visit to the clinician.
✔ Dominant health economics in comparison to standard of care.
✔ Early availability as a LDT through a CLIA certified high complexity laboratory.
Achievements
2020
Laboratory Developed MiCheck® Prostate Cancer Test Roll-out
2020
MiCheck® Pancreatic Cancer Study Commenced
2018
Completed MiCheck® Prostate Cancer Prospective Trial
2016
Awarded Accelerating Commercialization Grant to Further Product Development
2014
Clinical Validation Studies for MiCheck® Prostate Cancer Commenced
2011
Received Venture Capital Funding for Commercialization
2009
Showed Antibody Binding to Prostate Cancer Cells
2007
Minomic Formed to Pursue Opportunity in Biomarkers Based on MIL-38 Monoclonal Antibody
2015 Eureka Prize
Excellence in Interdisciplinary Scientific Research
Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.Address
Suite 2, Ground Floor,
75 Talavera Road,
Macquarie Park, NSW 2113,
Australia
Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here
Email
info@minomic.com
Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Headquarters of Minomic
